Clinical Study of Advanced Primary Hepatocellular Carcinoma Cells After TACE with use of Portal Vein Perfusion Chemothepary

Objective To study the efficacy of transcatheter arterial chemoembolization (TACE )and continuous portal vein perfusion chemothepary (VPC) on advanced hepatocellular carcinoma cells (HCC). Methods The patients in group A (n=83) received the epirubicin (EPI) 40 mg and the cisplatin (CDDP) 80mg, lipiodol-anticancer drug emulsion was injected into the feeding arteries of tumors followed by embolization with gelatin sponge (GS) particles. Patients in group B (n=59) after receiving the same as the group A then VPC was carried out. Results The response rate ( CR + PR) in group A and B was 45.8% and 61.0%(P0.05)respectively; the secondary respectable rate was 3.6% and 11.9% in group A and group B (P0.05)respectively. The survival rate for 1,2 and 3 gears in group A was 69.9%、60.2% and 20.5% respectively ;in group B was 96.6%,67.8% and 42.4% (P0.05)respectively. However.There was no marked difference in the incidente rate of complications between the two groups.Conclusion The therapeutic effect of TACE and VPC on HCC is better than that of TACE alone.